=Zafgen (FGEN) reported earnings on Mon 7 Aug 2017 (a/h)

Zafgen reports Q2 update

• Reports Q2 (Jun) loss of $0.49 per share, $0.03 better than the Capital IQ Consensus of ($0.52).
• Based on the positive data from the Company's Phase 1 clinical trial and preclinical data supporting a differentiated profile and improved safety margin versus first generation MetAP2 inhibitors, Zafgen plans to initiate a Phase 2 clinical trial, ZAF-1061-201, in the third quarter of this year in Australia and New Zealand. This clinical trial will be a three month assessment, enrolling approximately 120 patients with type 2 diabetes who are overweight or obese. Patients will be randomized 3:1 and will be assigned to either placebo or one of three ZGN-1061 dosing arms, 0.05 mg, 0.3 mg and 0.9 mg, which will be administered by subcutaneous injection every three days. The key objectives of this clinical trial are to assess glycemic control, body weight, as well as safety and tolerability, including coagulation related measures.
• As of June 30, 2017, the Company had cash, cash equivalents and marketable securities totaling $106.0 million.

FibroGen announces positive topline results of its Phase 2 study and two combination sub-studies of pamrevlumab in IPF; co also reports Q2 results

• Co announces positive topline results of its Phase 2 study and two combination sub-studies of pamrevlumab in idiopathic pulmonary fibrosis (IPF).
• "We are very encouraged by the topline IPF Phase 2 clinical study results that we announced today, in which pamrevlumab-treated patients had a significantly lower rate of decline in lung function, as compared to the placebo-treated patients. In addition, pamrevlumab continued to be well tolerated as a monotherapy in this IPF study, and was well tolerated in combination with pirfenidone and nintedanib..."We believe that the promising outcomes of these studies enable us to advance pamrevlumab into Phase 3 clinical development."
• Co also reports Q2 (Jun) loss of $(0.48) per share vs $(0.46) CapitalIQ consensus; revenue fell 68% YoY to $29.0 mln vs $34.3 mln consensus.